Total Payments
$17,003
2024 Payments
$2,601
Companies
43
Transactions
942
Medicare Patients
25,119
Medicare Billing
$2.9M
Payment Breakdown by Category
Food & Beverage$16,658 (98.0%)
Other$300.00 (1.8%)
Education$45.29 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,658 | 936 | 98.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $300.00 | 1 | 1.8% |
| Education | $45.29 | 5 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,430 | 231 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $2,151 | 119 | $0 (2024) |
| Amgen Inc. | $1,716 | 137 | $0 (2024) |
| PFIZER INC. | $1,356 | 102 | $0 (2024) |
| Abbott Laboratories | $1,339 | 26 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,096 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $938.87 | 53 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $867.03 | 28 | $0 (2024) |
| Amarin Pharma Inc. | $840.30 | 40 | $0 (2023) |
| Braemar Manufacturing, LLC | $443.10 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,601 | 130 | Abbott Laboratories ($777.57) |
| 2023 | $2,018 | 92 | Boehringer Ingelheim Pharmaceuticals, Inc. ($272.40) |
| 2022 | $2,307 | 124 | Amgen Inc. ($283.51) |
| 2021 | $1,562 | 104 | Janssen Pharmaceuticals, Inc ($352.72) |
| 2020 | $1,311 | 79 | Janssen Pharmaceuticals, Inc ($359.29) |
| 2019 | $2,207 | 139 | Janssen Pharmaceuticals, Inc ($546.54) |
| 2018 | $2,629 | 136 | Novartis Pharmaceuticals Corporation ($445.48) |
| 2017 | $2,368 | 138 | Novartis Pharmaceuticals Corporation ($421.44) |
All Payment Transactions
942 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $180.80 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/05/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $6.60 | General |
| Category: Cardiology | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $0.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/18/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/08/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $124.78 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $43.72 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Cardio-renal | ||||||
| 10/29/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $0.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/24/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $26.83 | General |
| Category: Medical Device | ||||||
| 10/21/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $22.94 | General |
| Category: Coronary | ||||||
| 10/18/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $25.99 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.63 | General |
| Category: Cardiovascular | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/14/2024 | Chiesi USA, Inc. | KENGREAL (Drug) | Food and Beverage | Cash or cash equivalent | $13.62 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $21.08 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $1.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $1.40 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $10.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.49 | General |
| Category: DIABETES | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $7.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 6,587 | 10,360 | $998,486 | $724,023 |
| 2022 | 30 | 6,596 | 10,255 | $1.0M | $762,446 |
| 2021 | 25 | 6,345 | 9,263 | $1.0M | $768,710 |
| 2020 | 24 | 5,591 | 8,210 | $915,887 | $682,680 |
Total Patients
25,119
Total Services
38,088
Medicare Billing
$2.9M
Procedure Codes
112
All Medicare Procedures & Services
112 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,737 | 2,397 | $316,991 | $227,970 | 71.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 744 | 750 | $152,186 | $111,270 | 73.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 304 | 304 | $136,401 | $104,710 | 76.8% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 303 | 603 | $71,289 | $53,170 | 74.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 260 | 750 | $61,946 | $48,372 | 78.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 186 | 186 | $32,758 | $22,477 | 68.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 193 | 211 | $29,063 | $22,239 | 76.5% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 93 | 789 | $29,169 | $22,227 | 76.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,532 | 1,671 | $25,797 | $18,468 | 71.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 305 | 305 | $22,321 | $15,087 | 67.6% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 82 | 719 | $20,857 | $14,518 | 69.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 119 | 119 | $18,875 | $13,985 | 74.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 85 | 338 | $32,110 | $13,717 | 42.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 115 | 388 | $12,002 | $8,864 | 73.9% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 119 | 396 | $9,104 | $6,725 | 73.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 86 | 86 | $5,999 | $4,332 | 72.2% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 40 | 40 | $5,975 | $4,250 | 71.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 30 | $5,557 | $4,226 | 76.0% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 33 | 40 | $3,245 | $2,298 | 70.8% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 40 | 48 | $2,773 | $2,100 | 75.7% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 37 | 38 | $999.68 | $781.65 | 78.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 34 | 34 | $833.38 | $557.06 | 66.8% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 26 | 28 | $666.53 | $490.20 | 73.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 23 | 23 | $489.44 | $367.98 | 75.2% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 16 | 16 | $403.26 | $297.72 | 73.8% |
About Dr. Mark Rubenstein, M.D
Dr. Mark Rubenstein, M.D is a Cardiovascular Disease healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457397580.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Rubenstein, M.D has received a total of $17,003 in payments from pharmaceutical and medical device companies, with $2,601 received in 2024. These payments were reported across 942 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($16,658).
As a Medicare-enrolled provider, Rubenstein has provided services to 25,119 Medicare beneficiaries, totaling 38,088 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 112 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boca Raton, FL
- Active Since 06/20/2006
- Last Updated 10/12/2011
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1457397580
Products in Payments
- XARELTO (Drug) $2,117
- ENTRESTO (Drug) $1,959
- Repatha (Biological) $1,234
- ELIQUIS (Drug) $1,200
- JARDIANCE (Drug) $1,022
- Vascepa (Drug) $840.30
- AVEIR (Device) $801.02
- FARXIGA (Drug) $499.09
- Corlanor (Drug) $481.44
- LEQVIO (Drug) $470.56
- Cardiac Monitoring Suite (Device) $443.10
- MULTAQ (Drug) $392.07
- VERQUVO (Drug) $348.99
- BRILINTA (Drug) $328.72
- VYNDAQEL (Drug) $318.31
- SOLIQUA (Drug) $300.00
- LifeVest (Device) $281.10
- Livalo (Drug) $279.54
- BYSTOLIC (Drug) $185.63
- FFRct (Device) $182.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boca Raton
Dr. Seth Baum, Md, MD
Cardiovascular Disease — Payments: $874,001
Cardiovascular Disease $874,001
David Funt, M.d, M.D
Cardiovascular Disease — Payments: $150,344
Cardiovascular Disease $150,344
Robert Ullman, Md, MD
Cardiovascular Disease — Payments: $40,434
Cardiovascular Disease $40,434
Dr. Aaron Bush, Md, MD
Cardiovascular Disease — Payments: $32,654
Cardiovascular Disease $32,654
Dr. Barry Merrill, Md, MD
Cardiovascular Disease — Payments: $29,164
Cardiovascular Disease $29,164
Dr. Andrew Panakos, M.d, M.D
Cardiovascular Disease — Payments: $19,328
Cardiovascular Disease $19,328